Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The objective of this study is to assess the risk of newly acquired RNA detection-proven SARS-CoV-2 infection after previous SARS-CoV-2 infection. This is a prospective study conducted from March to September 2020 in Barcelona, Spain. Healthcare workers caring for SARS-CoV-2 infected patients were divided in two cohorts: (a) previously RNA-proven SARS-CoV-2 infected cohort with mild symptoms (IC) and (b) healthy cohort (HC). Weekly SARS-CoV-2 RNA detection assays from nasopharyngeal swabs were performed. Serology status was assessed at the beginning and at the end of the study. Twenty participants were included in each group. The median age was 30 (IQR 27–34.75) years, and 55% were female. The median time of follow up was 49 (IQR 49–51) days. Fifteen out of 246 (6%) nasopharyngeal swab samples were positive for SARS-CoV-2, all in the IC. The percentage of participants in the IC with a probable newly acquired SARS-CoV-2 RNA-proven infection was 20% (95% IC 5.7–43.6%) at the end of the 7-week follow up period. The incidence reinfection rate was 28.6 (95% IC 7.8–73.2) cases per 1000 person-week. Despite detectable IgG antibodies against SARS-CoV-2 participants highly exposed to SARS-CoV-2 may develop a newly acquired SARS-CoV-2 RNA detection episode during the first months after the initial infection.

Details

Title
Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure
Author
Sánchez-Montalvá, Adrián 1 ; Fernández-Naval, Candela 2   VIAFID ORCID Logo  ; Antón, Andrés 2 ; Durà, Xavier 1 ; Vimes, Alba 3 ; Silgado, Aroa 2 ; Velásquez-Orozco, Fernando 2 ; Espinosa-Pereiro, Juan 1   VIAFID ORCID Logo  ; Salvador, Fernando 1   VIAFID ORCID Logo  ; Pumarola, Tomás 2 ; Almirante, Benito 1   VIAFID ORCID Logo  ; Esperalba, Juliana 2   VIAFID ORCID Logo 

 Infectious Diseases Department, Vall d’Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; [email protected] (X.D.); [email protected] (J.E.-P.); [email protected] (F.S.); [email protected] (B.A.) 
 Microbiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; [email protected] (C.F.-N.); [email protected] (A.A.); [email protected] (A.S.); [email protected] (F.V.-O.); [email protected] (T.P.); [email protected] (J.E.) 
 Clinical Pharmacology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; [email protected] 
First page
1968
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2530142023
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.